Novo Nordisk’s Winning Strategy In China Infiltrates County Hospital Market
This article was originally published in The Pink Sheet Daily
Ahead of the implementation of China’s newly expanded essential drug list, Novo Nordisk China Marketing VP Jack Chen talks to PharmAsia News about provincial tenders and the company’s strategy in the lower-tier markets.
You may also be interested in...
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.